Current Report Filing (8-k)
May 18 2020 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): May 17, 2020
TREVENA, INC.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
001-36193
|
|
26-1469215
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
955 Chesterbrook Boulevard, Suite 110
Chesterbrook, PA 19087
(Address of principal executive offices
and zip code)
Registrant’s telephone number, including
area code: (610) 354-8840
Not applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value
|
TRVN
|
The Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
o
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 7.01 Regulation FD Disclosure
In its May 15, 2020 issue, the journal Circulation published
online an article titled: β-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19, Manglik A, Wingler LM, Rockman,
HA, Lefkowitz, RJ. This article hypothesizes that targeting the AT1 receptor with a selective agonist, such as
TRV027, may offer a new approach to disrupting the cellular pathway that contributes to COVID-19-related acute respiratory distress
syndrome (ARDS). It also proposes the potential therapeutic advantage of this approach compared to angiotensin receptor blockers
(ARBs) and ACE inhibitors currently being investigated in clinical trials, due to the unique downstream signaling effects of an
AT1 receptor selective agonist. Trevena, Inc. (the “Company”) has received interest from multiple institutions
regarding potential studies that could evaluate the use of its investigational new drug, TRV027, in COVID-19 patients. TRV027
has previously been studied in 691 patients, completed a Phase 2b trial in acute heart failure, and has a well-established safety
profile.
Forward-Looking Statements
Any statements in this Current Report on Form 8-K about future
expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations,
clinical development and trials of its product candidates, and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “suggest,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to
the global COVID-19 pandemic; the status, timing, costs, results and interpretation of the Company’s clinical trials or any
future trials of any of the Company’s product candidates; the uncertainties inherent in conducting clinical trials; expectations
for regulatory interactions, submissions and approvals, including the Company’s assessment of the discussions with FDA and
the timing of FDA’s decision on the oliceridine NDA; available funding; and other factors discussed in the Risk Factors set
forth in the Company’s Annual Report on Form 10-K filed with the SEC and in other filings the Company makes with the SEC
from time to time. In addition, the forward-looking statements included in this report represent the Company’s views only
as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change.
However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims
any obligation to do so, except as may be required by law.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
TREVENA, INC.
|
|
|
Date: May 18, 2020
|
By:
|
/s/ Barry Shin
|
|
|
Barry Shin
|
|
|
Senior Vice President, Chief Financial Officer
|
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Apr 2023 to Apr 2024